HK Stock Market Move | TENNOR THERAP-B (06872) Surges 16% in Afternoon Session; First Patient Enrolled in Phase IIb Trial of TNP-2092 for Prosthetic Joint Infection

TENNOR THERAP-B (06872) surged 16% in the afternoon session. As of press time, it was up 4.71% at HK$97.8, with a turnover of HK$23.9277 million. On the news front, TenNor Therapeutics' investigational new drug candidate rifaquinozine (TNP-2092), administered via intra-articular injection for the treatment of prosthetic joint infection (PJI), has completed enrollment of the first patient in its multicenter Phase IIb clinical trial. The trial is designed to further evaluate the efficacy, safety, and pharmacokinetic profile of rifaquinozine in treating PJI without debridement or revision surgery, marking a key stage in the clinical development of this potentially disruptive new drug product. It is worth noting that TenNor Therapeutics announced that the company's board of directors has been granted a general mandate to repurchase the company's shares, with the maximum number of shares that may be repurchased not exceeding 5,232,900 shares. In view of the fact that the current market price of the company's shares does not fully reflect the company's intrinsic value and business development prospects, the company intends to repurchase shares on the open market under the repurchase mandate, with the total repurchase amount not exceeding RMB50 million.